Market Overview

Oxygen Biotherapeutics Announces $6M in Net Proceeds from Exercise of Warrants


Biotherapeutics (NASDAQ: OXBT) today announced the Company has received approximately $6
million through the exercise of 2,294,874 warrants between November 4,
2013 and November 6, 2013. These warrants were issued by the Company in
connection with its July 2013 Series C 8% Convertible Preferred Stock
financing. Following these warrant exercises, 9,112,307 shares of the
Company's common stock were issued and outstanding as of November 7,

“The exercise of these warrants increases our current cash on hand to
approximately $8.4 million. Upon closing of the previously announced
Phyxius Pharma transaction, we expect to be in a position to commence
the Phase 3

See full press release

Posted-In: News Guidance Contracts Asset Sales Management Global


Related Articles (OXBT)

View Comments and Join the Discussion!
Need corporate guidance data?
Click here to see licensing options.
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at